HQ Pharma

HQ Pharma is a China-based pharmaceutical R&D services and drug delivery company focused on complex formulations, improved new drugs, API development, clinical services, BE studies, and related CDMO activities. The company positions itself as a drug delivery system platform company with strengths in high-end sustained-release oral formulations, pediatric dosage forms, liposome emulsions, nanocrystal technologies, in situ gel systems, topical products, and sterile formulations. In addition to fee-for-service work, HQ Pharma has an internal portfolio of improved new drug programs, including an approved amisulpride orally disintegrating tablet in China. The company operates laboratories and pilot-scale capabilities in Shanghai, Zibo, and Jinan and serves both domestic and international pharmaceutical clients. Following a 2025 announced M&A and 2026 integration, it became a controlled subsidiary within China Meheco under General Technology Group.